CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
|Videos|October 14, 2021
- MHE October 2021
- Volume 31
- Issue 10
Manik Bhat Discusses "Managing Mission and Growth" and the Sacrifices Made by His Parents
Author(s)Peter Wehrwein
In this video segment, Bhat discusses his early career as community health worker in East Baltimore and starting and leading the growth of Healthify, a company that helps healthcare organizes address the social determinants of health. Healthify has recently been acquired by Wellsky and Bhat's title is vice president of SDOH operations and sales. Bhat also discusses the sacrifices his parents made for him and his brother and their work ethic.
Advertisement
Articles in this issue
almost 5 years ago
Emerging Health Leaders: Sonia Samagh of Stealth Venturealmost 5 years ago
Emerging Health Leaders: Andrew Toy, M.S., of Clover Healthalmost 5 years ago
Emerging Health Leaders: Evie Powell, Ph.D., of Proprioalmost 5 years ago
Emerging Health Leaders: Michael Palantoni of AthenahealthAdvertisement
Related to this article
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
One of teledentistry's most valuable applications is triage — helping a patient understand whether a concern can wait for an appointment, requires prompt attention or warrants emergency medical care.
Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.
In both mice and human cells, a small molecule selectively blocked the activity of MAP4K4, a protein involved in several major biological pathways.
Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Heather Burrell Ward, M.D., on personalizing TMS in schizophrenia
2
Texas A&M researchers discover promising therapy for fatty liver disease
3
FDA approves Lilly’s Onswik, the second once-weekly insulin
4
Teledentistry is a step in closing the gap in dental care
5